Versartis, Inc. (NASDAQ:VSAR) shares traded down 9.8% during mid-day trading on Tuesday . The stock traded as low as $2.00 and last traded at $2.03. 1,731,900 shares were traded during mid-day trading, an increase of 113% from the average session volume of 813,676 shares. The stock had previously closed at $2.25.
Several research analysts recently issued reports on the stock. Piper Jaffray Companies reiterated a “buy” rating and issued a $26.00 price target on shares of Versartis in a research note on Friday, September 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $14.00 price target (down from $34.00) on shares of Versartis in a research note on Friday, September 22nd. Morgan Stanley reiterated an “equal weight” rating and issued a $4.00 price target (up from $3.00) on shares of Versartis in a research note on Friday, September 22nd. Citigroup lowered shares of Versartis from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $23.00 to $3.00 in a research note on Monday, September 25th. Finally, Cowen restated an “outperform” rating and set a $45.00 price objective on shares of Versartis in a research note on Wednesday, August 23rd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $7.22.
The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.11.
In related news, Director Srinivas Akkaraju purchased 513,872 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were purchased at an average price of $2.21 per share, with a total value of $1,135,657.12. Following the acquisition, the director now directly owns 14,955 shares in the company, valued at approximately $33,050.55. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the firm’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $3.29, for a total transaction of $7,007,700.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,132,769 shares of company stock worth $7,014,761. Insiders own 10.90% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Orbimed Advisors LLC purchased a new stake in shares of Versartis during the 3rd quarter valued at about $123,000. Bank of America Corp DE boosted its holdings in shares of Versartis by 46.3% during the 1st quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 3,001 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Versartis during the 2nd quarter valued at about $218,000. Numeric Investors LLC purchased a new stake in shares of Versartis during the 2nd quarter valued at about $246,000. Finally, Voya Investment Management LLC boosted its holdings in shares of Versartis by 26.1% during the 2nd quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 3,094 shares during the last quarter. 49.18% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Versartis (VSAR) Trading Down 9.8%” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3080604/versartis-vsar-trading-down-9-8.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.